Han Myint
CIK 1840942 · View on SEC EDGAR ↗
First SEC filing: April 2, 2024 · Latest: April 2, 2024
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 29, 2024 | NXTC | A | 93,900 | — | — | 93,900 Direct | — | Acquired | (price as of 2026-08-20) |
| Jan. 31, 2024 | NXTC | A | 117,375 | — | — | 117,375 Direct | — | Acquired | (price as of 2026-08-20) |
| Feb. 28, 2023 | NXTC | A | 135,000 | — | — | 135,000 Direct | — | Acquired | (price as of 2026-08-20) |
| Jan. 31, 2022 | NXTC | A | 103,600 | — | — | 103,600 Direct | — | Acquired | (price as of 2026-08-20) |
| Jan. 13, 2021 | NXTC | A | 200,000 | — | — | 200,000 Direct | — | Acquired | (price as of 2026-08-20) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 29, 2024 | NXTC | Employee Stock Option (Right to Buy) | Common Stock (93,900) | $2.23 | March 28, 2034 | 93,900 | Acquired |
| Jan. 31, 2024 | NXTC | Employee Stock Option (Right to Buy) | Common Stock (117,375) | $1.22 | Jan. 30, 2034 | 117,375 | Acquired |
| Feb. 28, 2023 | NXTC | Employee Stock Option (Right to Buy) | Common Stock (135,000) | $1.55 | Feb. 27, 2033 | 135,000 | Acquired |
| Jan. 31, 2022 | NXTC | Employee Stock Option (Right to Buy) | Common Stock (103,600) | $5.57 | Jan. 30, 2032 | 103,600 | Acquired |
| Jan. 13, 2021 | NXTC | Employee Stock Option (Right to Buy) | Common Stock (200,000) | $12.09 | Jan. 12, 2031 | 200,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
NXTC
M.D., FACP(5) former Chief Medical Officer| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2023 | $461,963 | — | — | $151,269 | $68,800 | — | $15,900 | $697,932 |
| 2022 | $445,413 | — | — | $398,860 | $98,200 | — | $10,845 | $953,318 |
| 2021 | $415,341 | $75,000 | — | $1,650,000 | $119,600 | — | $2,041 | $2,261,982 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.